Latest Breaking News On - International non proprietary name - Page 1 : comparemela.com

Penetration rate of generic and biosimilar drugs in Tunisia estimated at 55%

Penetration rate of generic and biosimilar drugs in Tunisia estimated at 55%
tanzanianewsreports.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tanzanianewsreports.com Daily Mail and Mail on Sunday newspapers.

Mehdi dridiWorld health organisationWorld bankInternational nameInternational days of genericCentral pharmacyTunisia mehdi dridiInternational daysBiosimilar medicinesInternational non proprietary nameAgence tunis afrique presse

tap.info.tn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tap.info.tn Daily Mail and Mail on Sunday newspapers.

Mehdi dridiInternational days of genericInternational nameWorld bankWorld health organisationCentral pharmacyTunisia mehdi dridiInternational daysBiosimilar medicinesInternational non proprietary name

Form 20-F KAZIA THERAPEUTICS LTD For: Jun 30

Form 20-F KAZIA THERAPEUTICS LTD For: Jun 30
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSoult ukpyolsiSouth koreaIsrael generalCity ofUnited kingdomNew south walesNew zealandSan franciscoDana farber cancer instituteNorth carolinaHong kongMemorial sloan kettering cancer centerUniversity of utahDistrict of columbia

AIIMS declares it premises drugs-free zone; strict punishment for offenders

The All India Institute of Medical Sciences here on Tuesday declared its premises a drugs-free zone, recommending action against staff, students and patients/attendants violating the Narcotic Drugs and Psychotropic Substances Act (1985) on its .

New delhiInternational nameIndia institute of medical sciencesAll india instituteMedical sciencesNarcotic drugsPsychotropic substances actInternational non proprietary name

CellCentric secures investment from American Cancer Society s impact venture capital fund to advance inobrodib, its ground-breaking p300/CBP targeted therapy

/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.

United statesUnited kingdomNorth lanarkshireAlice pomponioPrnewswire cellcentricJason dingesInternational nameMorningside investmentsAmerican cancer society brightedgeMorningside technology advisoryAmerican cancer societyWorld health organisationAmerican cancerAndrogen receptorInternational non proprietary nameManaging director